Page 4 - Open Label News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Open Label. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Open Label Today - Breaking & Trending Today

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

Published: August 16, 2022

ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 monotherapy in patients with advanced tumors and hematologic malignancies. SHANGHAI and HONG KONG, Aug. 16, 2022 /PRNewswire/ --Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical com...

Source: singaporestar.com

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Published: June 23, 2022

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and currently only, investigational oral SERD with positive topline results Additional data presented at SABCS (December 2021) and ASCO (June 2022) Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON, June 23, 2022 /PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. (...

Source: singaporestar.com

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Published: June 14, 2022

SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ --Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announcedthat the first patient has been dosed in the Phase I STAMINA-001 trial to evaluate ATG-037 as a monotherapy or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors in Australia. The primary objective of the study is ...

Source: singaporestar.com

Four Poster Presentations at 2022 ASCO Annual Meeting

Published: June 7, 2022

NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in... | June 7, 2022

Source: marketscreener.com

OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi in Immuno-Oncology at ASCO 2022

Published: May 23, 2022

23.05.2022 - Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring ... Seite 1

Source: wallstreet-online.de